Study summary

Adding cetuximab to immunotherapy nearly quadrupled time to progression

Alliance A091802 trial · 60 people, randomized phase 2 · Published May 2025, Journal of Clinical Oncology

What was tested

Avelumab, a PD-L1 immunotherapy, with or without cetuximab, an EGFR antibody, for advanced cutaneous squamous cell carcinoma.

What they found

• Median progression-free survival was 11.1 vs 3.0 months (hazard ratio 0.48).
• Severe side effects were more common with the combination (48.3% vs 21.5%).

What it means

Supports combining EGFR antibodies with immunotherapy, especially for people who cannot take immunotherapy alone well.